BILLERICA, Mass. / May 09, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business. Bruker also expects to provide an update to its medium-term financial outlook.
The Investor Webinar will include presentations by CEO Frank H. Laukien, CFO Gerald Herman, and by the leaders of these three new Bruker businesses, all followed by a live Q&A session for analysts and investors.
A link to the Investor Webinar will be available in the Events & Presentations section of the Company’s Investor Relations website at https://ir.bruker.com. A replay will be available on Bruker’s Investor Relations website after the conclusion of the event.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Last Trade: | US$38.30 |
Daily Change: | 0.61 1.62 |
Daily Volume: | 1,082,979 |
Market Cap: | US$5.810B |
June 03, 2025 June 02, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load